Innovation comes with hefty price tag as biopharma R&D spend climbs

To keep biopharmaceutical innovation churning requires mountains of cash. Companies will need to invest as much as $2.5 billion over a 10- to 15-year period in order to bring a new therapy to the marketplace, according to a 2014 study conducted by the Tufts Center for the Study of Drug Development.

Read more >

Roche’s Ocrevus to dominate the multiple sclerosis market

As it enters the market, Ocrevus (ocrelizumab) is a drug set not only to top the multiple sclerosis (MS) field, but also to be 2017’s biggest future-blockbuster entrant. The 2017 edition of the annual Drugs to Watch report forecasts that seven new drugs including Ocrevus will enter the market in 2017 and achieve blockbuster sales of more than 1 billion by 2021, as evaluated by consensus sales forecast data from Clarivate Analytics Cortellis Competitive Intelligence (source Thomson Reuters I/B/E/S).

Read more >

The 3 Rs of cancer research: rigor, reproducibility and robustness

As scientists gathered at the 2017 meeting of the American Association for Cancer Research (AACR) in Washington in early April to learn about the latest advances in cancer research, one of the questions was how much of that research would hold up to attempts to reproduce it.

Read more >

VC investments hit status quo in Q1, but no complaints here

Last year wasn't the best for venture capital investments in U.S. private companies, with the total for the year headed in the wrong direction, failing to match 2015 levels.

Read more >

Reaching Beyond the Data to Prevent Target Identification Failure

Finding new drugs and bringing them to market is a long, research-intensive process, taking on average 10 to 12 years and costing between $1.5 billion and $3 billion.

Read more >